Key points are not available for this paper at this time.
Increased utilization of glutamine is characteristic of many advanced, aggressive cancers. Established glutamine imaging strategies require the use of labeled probes (positron emission tomography, hyperpolarized spectroscopy) that can limit their accessibility. Here, we investigated the utility of chemical exchange saturation transfer (CEST) MRI upon intravenous injection of unlabeled alanine to monitor differences in cellular glutamine uptake as a potentially complementary imaging biomarker for profiling cancers and monitoring their progression.
Ghaemi et al. (Wed,) studied this question.